News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Submit a Press Release
Submit an Event
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
742,392 Results
Type
Article (43831)
Company Profile (318)
Press Release (698229)
Multimedia
Podcasts (116)
Webinars (19)
Section
Business (210993)
Career Advice (2109)
Deals (36760)
Drug Delivery (124)
Drug Development (83421)
Employer Resources (176)
FDA (16831)
Job Trends (15503)
News (357378)
Policy (34132)
Tag
2027 BioMidwest Elite (1)
2027 Biotech Bay Standard (2)
2027 Biotech Beach Elite (1)
2027 Genetown Elite (3)
2027 Pharm Country Elite (1)
2027 Pharm Country Standard (3)
Academia (2616)
Accelerated approval (34)
Adcomms (26)
Allergies (150)
Alliances (51584)
ALS (174)
Alzheimer's disease (1699)
Antibody-drug conjugate (ADC) (327)
Approvals (17096)
Artificial intelligence (543)
Autoimmune disease (162)
Automation (42)
Bankruptcy (372)
Best Places to Work (11770)
BIOSECURE Act (21)
Biosimilars (198)
Biotechnology (188)
Bladder cancer (160)
Brain cancer (61)
Breast cancer (655)
Cancer (4935)
Cardiovascular disease (421)
Career advice (1788)
Career pathing (37)
CAR-T (287)
CDC (49)
Celiac Disease (2)
Cell therapy (763)
Cervical cancer (36)
Clinical research (71210)
Collaboration (1776)
Company closure (4)
Compensation (1181)
Complete response letters (65)
COVID-19 (2788)
CRISPR (99)
C-suite (890)
Cystic fibrosis (148)
Data (6337)
Decentralized trials (2)
Denatured (36)
Depression (138)
Diabetes (510)
Diagnostics (6797)
Digital health (49)
Diversity (12)
Diversity, equity & inclusion (45)
Drug discovery (263)
Drug pricing (202)
Drug shortages (31)
Duchenne muscular dystrophy (235)
Earnings (91992)
Editorial (61)
Employer branding (21)
Employer resources (155)
Events (120363)
Executive appointments (1008)
FDA (20014)
Fibrodysplasia Ossificans Progressiva (7)
Friedreich's ataxia (11)
Frontotemporal dementia (23)
Funding (1498)
Gene editing (206)
Generative AI (46)
Gene therapy (617)
GLP-1 (1015)
Government (4810)
Grass and pollen (7)
Guidances (385)
Healthcare (19066)
HIV (62)
Huntington's disease (46)
IgA nephropathy (86)
Immunology and inflammation (266)
Immuno-oncology (61)
Indications (119)
Infectious disease (3065)
Inflammatory bowel disease (201)
Inflation Reduction Act (14)
Influenza (119)
Intellectual property (259)
Interviews (327)
IPO (16921)
IRA (57)
Job creations (4070)
Job search strategy (1498)
JPM (64)
Kidney cancer (16)
Labor market (86)
Layoffs (576)
Leadership (34)
Legal (8425)
Liver cancer (92)
Longevity (16)
Lung cancer (665)
Lymphoma (385)
Machine learning (43)
Management (60)
Manufacturing (837)
MASH (170)
Medical device (13865)
Medtech (13921)
Mergers & acquisitions (20915)
Metabolic disorders (1311)
Multiple sclerosis (164)
NASH (17)
Neurodegenerative disease (328)
Neuropsychiatric disorders (92)
Neuroscience (2973)
Neurotech (1)
NextGen: Class of 2026 (6644)
Non-profit (4563)
Now hiring (68)
Obesity (620)
Opinion (289)
Ovarian cancer (168)
Pain (217)
Pancreatic cancer (232)
Parkinson's disease (286)
Partnered (34)
Patents (515)
Patient recruitment (502)
Peanut (60)
People (60952)
Pharmaceutical (90)
Pharmacy benefit managers (31)
Phase 1 (22103)
Phase 2 (31308)
Phase 3 (23460)
Pipeline (5491)
Policy (303)
Postmarket research (2655)
Preclinical (9390)
Press Release (68)
Prostate cancer (242)
Psychedelics (50)
Radiopharmaceuticals (290)
Rare diseases (881)
Real estate (6306)
Recruiting (72)
Regulatory (25453)
Reports (53)
Research institute (2441)
Resumes & cover letters (361)
Rett syndrome (27)
RNA editing (17)
RSV (81)
Schizophrenia (156)
Series A (246)
Series B (194)
Service/supplier (11)
Sickle cell disease (100)
Special edition (25)
Spinal muscular atrophy (160)
Sponsored (43)
Startups (3766)
State (2)
Stomach cancer (19)
Supply chain (107)
Tariffs (96)
The Weekly (78)
Vaccines (1043)
Venture capital (91)
Weight loss (405)
Women's health (94)
Worklife (18)
Date
Today (48)
Last 7 days (576)
Last 30 days (2367)
Last 365 days (30229)
2026 (4046)
2025 (30680)
2024 (35767)
2023 (40629)
2022 (51798)
2021 (56329)
2020 (54791)
2019 (47397)
2018 (35770)
2017 (33137)
2016 (32662)
2015 (38615)
2014 (32516)
2013 (27630)
2012 (29729)
2011 (30487)
2010 (28497)
Location
Africa (800)
Alabama (84)
Alaska (7)
Arizona (318)
Arkansas (14)
Asia (42171)
Australia (6753)
California (11465)
Canada (3342)
China (1143)
Colorado (483)
Connecticut (486)
Delaware (345)
Europe (90448)
Florida (1717)
Georgia (361)
Hawaii (3)
Idaho (61)
Illinois (889)
India (72)
Indiana (537)
Iowa (22)
Japan (448)
Kansas (127)
Kentucky (40)
Louisiana (26)
Maine (72)
Maryland (1404)
Massachusetts (8249)
Michigan (330)
Minnesota (635)
Mississippi (5)
Missouri (128)
Montana (32)
Nebraska (28)
Nevada (123)
New Hampshire (79)
New Jersey (3046)
New Mexico (29)
New York (3026)
North Carolina (1492)
North Dakota (8)
Northern California (5600)
Ohio (339)
Oklahoma (22)
Oregon (46)
Pennsylvania (2322)
Puerto Rico (24)
Rhode Island (48)
South America (1175)
South Carolina (68)
South Dakota (1)
Southern California (4468)
Tennessee (177)
Texas (1770)
United States (40761)
Utah (343)
Vermont (1)
Virginia (280)
Washington D.C. (81)
Washington State (937)
West Virginia (4)
Wisconsin (117)
Wyoming (2)
742,392 Results for "biocryst pharmaceuticals inc".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Press Releases
BioCryst to Present at Upcoming March 2026 Investor Conference
February 17, 2026
·
1 min read
Mergers & acquisitions
BioCryst Snaps Up Fellow Angiodema Player Astria for $700M
The acquisition will give BioCryst an investigational injectable drug for hereditary angioedema, potentially complementing its FDA-approved oral drug Orladeyo.
October 15, 2025
·
2 min read
·
Tristan Manalac
Press Releases
Astria Stockholders Vote to Approve Acquisition by BioCryst
January 22, 2026
·
2 min read
Press Releases
BioCryst to Report Fourth Quarter 2025 Financial Results on February 26
February 5, 2026
·
1 min read
Press Releases
BioCryst Completes Acquisition of Astria Therapeutics, Expanding Leadership in Hereditary Angioedema
January 26, 2026
·
7 min read
Press Releases
BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - February 5, 2026
February 5, 2026
·
1 min read
Press Releases
BioCryst to Present at 44th Annual J.P. Morgan Healthcare Conference
January 6, 2026
·
1 min read
Press Releases
BioCryst to Present New HAE Data from ORLADEYO® (berotralstat) and Navenibart at the 2026 American Academy of Allergy, Asthma & Immunology Annual Meeting
February 11, 2026
·
8 min read
Press Releases
BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - January 6, 2026
January 6, 2026
·
1 min read
Press Releases
BioCryst Receives Early Termination of HSR Waiting Period for Astria Acquisition
December 3, 2025
·
7 min read
1 of 74,240
Next
